Literature DB >> 15211254

[Alveolar hypoxemic interstitial pneumonia related to rituximab therapy].

V Jullien1, C Perrin, F Peyrade, F Lemoigne, R-M Chichmanian, B Blaive.   

Abstract

INTRODUCTION: Rituximab is indicated for the treatment of low-grade lymphoma. Pulmonary toxicity related to rituximab is exceptional. CASE REPORT: Here we report a patient with non-Hodgkin lymphoma treated with "CHOP" chemotherapy (cyclophosphosphamide, adriamycin, vincristine and prednisolone) and rituximab who developed an interstitial pneumonia with acute respiratory failure. The differential diagnosis of this clinical and radiological diagnosis is discussed.
CONCLUSION: Although cases of interstitial pneumonia associated with rituximab are rare, they may be severe and thus any patient experiencing respiratory symptoms on this therapy should be monitored closely.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15211254     DOI: 10.1016/s0761-8425(04)71304-2

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  2 in total

Review 1.  New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.

Authors:  Frederico F Souza; Andrew Smith; Cyrillo Araujo; Jyothi Jagannathan; Ciaran Johnston; Kevin O'Regan; Atul Shinagare; Nikhil Ramaiya
Journal:  Cancer Imaging       Date:  2014-07-23       Impact factor: 3.909

2.  Acute respiratory distress syndrome after rituximab infusion.

Authors:  Alberto J Montero; John J McCarthy; George Chen; Lawrence Rice
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.